Schematic model of TAK-981–mediated antitumor innate immune responses through IFN1 activation. TAK-981 treatment enhances M1 macrophage polarization and NK cell activation through IFN1 signaling, leading to enhanced macrophage phagocytosis and NK cell cytotoxicity against tumor cells, particularly in the presence of therapeutic monoclonal antibodies like rituximab. The induction of activating FCGR levels in macrophages following TAK-981 treatment may also contribute to the enhanced macrophage phagocytosis.